Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues
Sabrina Porta, Ãlvaro Danza, Maira Arias Saavedra, Adriana Carlomagno, María Cecilia Goizueta, Florencia Vivero, Guillermo Ruiz‐Irastorza
Abstract
Since the discovery of glucocorticoids (GCs), their important anti-inflammatory effect, rapid mechanism of action, low cost, and accessibility have made them one of the mainstays of treatment for Systemic lupus erythematosus (SLE). Although their use has allowed controlling the disease and reducing acute mortality in severe conditions, the implementation of a scheme based on high doses for long periods has inevitably been accompanied by an increase in adverse effects and infections, including long-term damage. The objective of this review is to answer some important questions that may arise from its use in daily clinical practice, and to propose a paradigm based on the use of methylprednisolone pulses followed by medium-low doses and a rapid decrease of prednisone.